22.57
price up icon1.30%   0.29
after-market Handel nachbörslich: 22.58 0.010 +0.04%
loading
Schlusskurs vom Vortag:
$22.28
Offen:
$22.17
24-Stunden-Volumen:
917.69K
Relative Volume:
0.44
Marktkapitalisierung:
$3.78B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
125.39
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+2.54%
1M Leistung:
-0.62%
6M Leistung:
+26.73%
1J Leistung:
+24.49%
1-Tages-Spanne:
Value
$22.13
$22.64
1-Wochen-Bereich:
Value
$21.96
$23.12
52-Wochen-Spanne:
Value
$13.40
$25.23

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Firmenname
Acadia Pharmaceuticals Inc
Name
Telefon
858-558-2871
Name
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Name
Mitarbeiter
654
Name
Twitter
@acadiapharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
ACAD's Discussions on Twitter

Vergleichen Sie ACAD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
22.57 3.68B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-21 Hochstufung Deutsche Bank Hold → Buy
2025-02-11 Eingeleitet Deutsche Bank Hold
2025-01-03 Herabstufung Guggenheim Buy → Neutral
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-03-12 Herabstufung Mizuho Buy → Neutral
2024-03-12 Bestätigt Needham Buy
2024-01-30 Eingeleitet Robert W. Baird Outperform
2024-01-24 Hochstufung Needham Hold → Buy
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-12-14 Herabstufung Deutsche Bank Buy → Hold
2023-12-13 Eingeleitet Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-11-06 Hochstufung Mizuho Neutral → Buy
2023-10-17 Eingeleitet UBS Buy
2023-10-10 Hochstufung JP Morgan Neutral → Overweight
2023-01-03 Hochstufung Guggenheim Neutral → Buy
2022-11-04 Herabstufung Goldman Neutral → Sell
2022-11-01 Eingeleitet Loop Capital Hold
2022-08-08 Herabstufung Citigroup Buy → Neutral
2022-08-05 Herabstufung Citigroup Buy → Neutral
2022-06-21 Herabstufung Jefferies Buy → Underperform
2022-06-16 Hochstufung Jefferies Hold → Buy
2022-03-16 Hochstufung Canaccord Genuity Hold → Buy
2022-02-09 Hochstufung H.C. Wainwright Neutral → Buy
2022-01-05 Hochstufung Citigroup Neutral → Buy
2021-12-21 Herabstufung Guggenheim Buy → Neutral
2021-11-01 Hochstufung Guggenheim Neutral → Buy
2021-10-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-23 Fortgesetzt Needham Hold
2021-06-10 Eingeleitet Berenberg Hold
2021-04-07 Herabstufung H.C. Wainwright Buy → Neutral
2021-04-06 Herabstufung Canaccord Genuity Buy → Hold
2021-04-06 Herabstufung Goldman Buy → Neutral
2021-04-06 Herabstufung Jefferies Buy → Hold
2021-04-06 Herabstufung Mizuho Buy → Neutral
2021-04-05 Herabstufung Raymond James Outperform → Mkt Perform
2021-03-10 Herabstufung BofA Securities Buy → Neutral
2021-03-09 Herabstufung Citigroup Buy → Neutral
2021-03-09 Herabstufung Guggenheim Buy → Neutral
2021-03-09 Bestätigt H.C. Wainwright Buy
2021-03-09 Herabstufung Raymond James Strong Buy → Outperform
2021-03-09 Herabstufung Stifel Buy → Hold
2020-12-16 Eingeleitet Mizuho Buy
2020-11-16 Hochstufung Raymond James Outperform → Strong Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-20 Eingeleitet Morgan Stanley Overweight
2020-07-07 Hochstufung Stifel Hold → Buy
2020-04-16 Eingeleitet Jefferies Buy
2020-03-31 Hochstufung Goldman Neutral → Buy
2020-03-06 Eingeleitet Citigroup Buy
2019-12-16 Eingeleitet Guggenheim Buy
2019-10-24 Eingeleitet Oppenheimer Perform
2019-10-01 Eingeleitet RBC Capital Mkts Outperform
2019-09-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-10 Hochstufung Canaccord Genuity Hold → Buy
2019-07-23 Bestätigt Needham Buy
2018-12-10 Eingeleitet Canaccord Genuity Hold
2018-09-21 Hochstufung Piper Jaffray Neutral → Overweight
2018-08-09 Bestätigt Stifel Hold
2018-08-07 Eingeleitet Stifel Hold
2018-08-06 Herabstufung Piper Jaffray Overweight → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

pulisher
Jul 22, 2025

Is ACADIA Pharmaceuticals Inc. a good long term investmentTremendous return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ACADIA Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on assets - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives ACADIA Pharmaceuticals Inc. stock pricePhenomenal investment performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about ACADIA Pharmaceuticals Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN

Jul 19, 2025
pulisher
Jul 17, 2025

Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Jul 17, 2025
pulisher
Jul 15, 2025

Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

What makes ACADIA Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 10, 2025

The $12 Billion Opportunity Bolstering This Biotech Stock - Investor's Business Daily

Jul 10, 2025
pulisher
Jul 07, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com Australia

Jul 07, 2025
pulisher
Jul 03, 2025

Acadia Pharmaceuticals Rides High On Patent Wins And Strong Pipeline - Finimize

Jul 03, 2025
pulisher
Jul 03, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 03, 2025
pulisher
Jul 02, 2025

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive

Jul 02, 2025
pulisher
Jun 29, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Jun 29, 2025
pulisher
Jun 27, 2025

Acadia Pharmaceuticals' Stocks Undervalue Future Blockbuster Potential - Finimize

Jun 27, 2025
pulisher
Jun 26, 2025

ACAD: ACADIA Pharmaceuticals Receives Buy Rating from Needham | ACAD Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Acadia Pharmaceuticals Stock Price Undervalues Potential Market Opportunity of Nuplazid, Daybue, RBC Says - MarketScreener

Jun 26, 2025
pulisher
Jun 25, 2025

Acadia plans seven late-stage trials, five readouts through 2027 - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by RBC Capital | ACAD Stock News - GuruFocus

Jun 23, 2025
pulisher
Jun 23, 2025

Learn to Evaluate (ACAD) using the Charts - news.stocktradersdaily.com

Jun 23, 2025
pulisher
Jun 20, 2025

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - MSN

Jun 20, 2025
pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule. - AInvest

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

Acadia wins patent appeal for key drug composition - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Acadia gets court approval related to Nuplazid patent - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review

Jun 10, 2025

Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):